Trial Profile
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation for Children With Non-Malignant Diseases Who Have Been Multiply Transfused: a Pilot Study.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Alefacept (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 09 May 2017 Status changed from suspended to discontinued.
- 04 Apr 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
- 28 Mar 2011 New trial record